Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
6.44
+0.01 (0.16%)
At close: Apr 28, 2026, 4:00 PM EDT
6.44
0.00 (0.00%)
After-hours: Apr 28, 2026, 5:42 PM EDT
Company Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Minerva Neurosciences, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 1, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Remy Luthringer |
Contact Details
Address: 1500 District Avenue Burlington, Massachusetts 01803 United States | |
| Phone | 617 600 7373 |
| Website | minervaneurosciences.com |
Stock Details
| Ticker Symbol | NERV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001598646 |
| CUSIP Number | 603380205 |
| ISIN Number | US6033802058 |
| Employer ID | 26-0784194 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman and Chief Executive Officer |
| Frederick W. Ahlholm CPA | Senior Vice President, Chief Financial Officer and Secretary |
| Joseph Reilly | Senior Vice President and Chief Operating Officer |
| William B. Boni | Vice President of Investor Relations and Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2026 | ARS | Filing |
| Apr 23, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 6, 2026 | 8-K | Current Report |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 144 | Filing |
| Mar 31, 2026 | 144 | Filing |
| Mar 31, 2026 | 144 | Filing |
| Mar 19, 2026 | EFFECT | Notice of Effectiveness |